Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$101.14 USD
-2.01 (-1.95%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $101.28 +0.14 (0.14%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$101.14 USD
-2.01 (-1.95%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $101.28 +0.14 (0.14%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
by Zacks Equity Research
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
by Zacks Equity Research
AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.
Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion
by Zacks Equity Research
Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.
Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data
by Zacks Equity Research
Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
by Zacks Equity Research
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
by Zacks Equity Research
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.
Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline
by Zacks Equity Research
Eli Lilly (LLY) to buy an early phase oncology asset, AK-01, from AurKa Pharma to expand its oncology pipeline.
Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents
by Zacks Equity Research
The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.
Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat
by Zacks Equity Research
Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.
Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down
by Zacks Equity Research
Geron (GERN) beats earnings but on lower sales in Q1. Operating expenses were lower year over year.
Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Intrexon (XON) incurs narrower-than-expected loss but revenues missed mark in the first quarter of 2018.
Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up
by Zacks Equity Research
Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.
Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View
by Ekta Bagri
Valeant's (VRX) first-quarter earnings topped estimates driven by growth in Bausch + Lomb/International segment and Salix businesses. The company also upped its view.
Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings
by Ekta Bagri
Endo's (ENDP) first-quarter results beat earnings on both counts driven by growth in Xiaflex and sterile injectables.
Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses
by Zacks Equity Research
Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.
VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
by Zacks Equity Research
VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.
Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down
by Zacks Equity Research
Puma Biotechnology (PBYI) Q1 loss per share is narrower than the Zacks Consensus Estimate while sales misses the same.
Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View
by Zacks Equity Research
Infinity (INFI) reports in-line loss in Q1 and maintains its 2018 guidance.
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Epizyme (EPZM) betters loss estimates in Q1 and expects to file a new drug application to the FDA for its lead pipeline candidate tazemetostat in fourth-quarter 2018.
Ligand (LGND) Beats on Q1 Earnings & Revenues, Keeps View
by Zacks Equity Research
Ligand (LGND) beats both earnings and sales estimates in the first quarter of 2018. The company repeats its previous guidance for 2018.
Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y
by Zacks Equity Research
Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q1. Revenues surge year over year on increasing sales of Vibativ and collaborative revenues.
AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.
Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Merrimack (MACK) reports wider-than-expected loss in the first quarter.
Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q1 and also raises the lower end of its earnings and sales guidance for 2018.